Influenza and other respiratory viruses · 2026
Effectiveness of 2024/25 KP.2 Vaccine Against Outpatient COVID-19 in Canada.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Separovic Lea, Sabaiduc Suzana, Zhan Yuping, Kaweski Samantha E, Carazo Sara, Olsha Romy, Mather Richard G, Lacroix Christine, Hasso Maan, Levade Inès, Meunier Isabelle, Jassem Agatha N, Dover Katie, Gao Ruimin, Bastien Nathalie, Skowronski Danuta M
Аннотация
The Canadian Sentinel Practitioner Surveillance Network used the test-negative design to assess KP.2 vaccine effectiveness (VE) against medically attended outpatient COVID-19 between November 2024 and April 2025 among participants ≥ 12 years. Analyses included 5410 controls (19% vaccinated) and 435 COVID-19 cases (10% vaccinated). Nearly three-quarters (72%) of contributing case viruses were genetically characterized, with XEC (35%) and KP.3.1.1 (38%) variants most commonly identified. Vaccination reduced COVID-19 risk by approximately half (54%; 95% CI: 36-68) relative to unvaccinated individuals. VE was greatest during the first 2 months postvaccination, reducing risk by two-thirds and declining to minimal protection by the fifth month postvaccination.